BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Clinical trials for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS explained in plain language.
Never miss a new study
Get alerted when new BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS trials appear
Sign up with your email to follow new studies for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough leukemia: vyxeos targets cancer cells after standard chemo fails
Disease control Recruiting nowThis study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after the first round of standard chemotherapy. Vyxeos combines two common chemo drugs inside a tiny fat bubble (liposome) to deliver them more directly to cancer cells,…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Experimental drug combo offers hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial is for people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) whose cancer came back or didn't respond to standard therapy. The study tests a chemotherapy drug combo called CPX-351 to find the safest dose and see if …
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New hope for rare blood disorder: ruxolitinib trial targets eosinophils
Disease control Recruiting nowThis study tests the drug ruxolitinib in 10 people with hypereosinophilic syndrome or related disorders, where high levels of eosinophils (a type of white blood cell) cause organ damage. The goal is to see if ruxolitinib can lower eosinophil counts and improve symptoms. Participa…
Matched conditions: BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS
Phase: PHASE2 • Sponsor: William Shomali • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC